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1. Introduction
Ph+  ALL  represents  approximately  about  25  to  40%  of  adults  patients  with  ALL.  In
children, Ph+ ALL is much less common. Different breakpoint in the bcr gene, major and
minor, produce fusion genes resulting in either a 210 or a 190 KDa protein respectively. It
appears that major breakpoint fusion (p210) originates in hematopoietic stem cells whereas
minor breakpoint fusion (p190) has a B cell progenitor origin, suggesting that p190 ALL
and p210 Ph+ ALL may be distinct biological and clinical entities. [1] BMT is the first option
for consolidation the complete remission in this patients. The proportion of patients able
to undergo BMT in CR1 (Complete Remission) has increased with imatinib-based induc‐
tion and early post-remission therapy, and there is currently no evidence that imatinib has
an adverse effect on transplant-related morbidity or mortality (TMR). In addition, donor
availability  has  benefitted  from  results  showing  equivalence  of  sibling  and  matched
unrelated donors in terms of remission duration, non-relapse mortality and overall survival
(OS).[1,  2]  Several  studies  have  shown  improved  post-transplant  outcome  of  patients
previously  receiving  imatinib-based  treatment  when  compared  with  historic  control
groups, which have been dealt with in the previous chapter. As a consequence, most ALL
study groups currently consider imatinib-based treatment, followed by matched related or
unrelated allogeneic SCT (allo-SCT) in CR1, to be the gold standard of first-line therapy
for  Ph+ ALL.  [3],  Imatinib-based treatment  not  followed by SCT has  been suggested to
achieve OS and Disease Free Survival (DFS) similar to that obtained after SCT in one study,
[4] and the results of MDACC study showed only a trend towards better OS in transplant‐
ed patients. [5] It still needs to be determined whether therapy based on second genera‐
tion TKI may be equivalent or superior to BMT in a subset of patients, particularly those
at high risk of TRM
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The challenges in the treatment of Ph+ ALL are the selection of appropriate pre-transplantation
therapy, the minimization of transplantation toxicity, the correct use of TKIs after transplan‐
tation and the appropriate use of and response to BCR/ABL monitoring.
2. Allogeneic stem cell transplantation with myeloablative conditioning
Attempts to improve outcome of Ph+ ALL included intensified conditioning regimens in order
to reduce the relapse rate. An intensified preparatory regimen consisting of SCT after fractio‐
nated total body irradiation and Cyclophosphamide with or without etoposide has been
explored by different investigation groups. Kröger et al investigated an intensified condition‐
ing regimen including fractionated total body irradiation (TBI) (12 Gy), etoposide (30-45
mg/kg) and cyclophosphamide (120 mg/kg), followed by autologous (n = 5), allo-related (n =
13) or allo-unrelated (n = 6) bone marrow (n = 22) or peripheral stem cell (n = 2) transplantation
in patients with Ph+ALL. One patient received busulfan (16 mg/kg) instead of TBI. Nineteen
patients were transplanted in 1CR, two in 2CR, one in 1PR and two in relapse. After a median
follow-up of 45 months, nine patients (37.5%) remain alive in CR. Nine patients (37.5%)
relapsed and eight (33.3%) of these subsequently died. After autologous transplantation, four
of five patients (80%) relapsed and died. In terms of late relapse the authors had seen it after
allogeneic, as well as autologous transplantation, at 33 and 59 months, respectively. The
Kaplan-Meier estimate of leukemia-free survival for all patients was 38% at 3 years and 35%
at 5 years. For allogeneic transplants in first CR (n = 15) the estimate of DFS was 46% at 3 years
and 34% at 5 years. Patients aged below 30 years had a better estimated OS at 3 years (61% vs
11%, P < 0.001). The bcr-abl fusion transcript (p210 vs p190 vs p210/190) did not affect DFS OR
OS. For the authors an intensified conditioning regimen seems to improve the results of bone
marrow transplantation in patients with Ph+ acute lymphoblastic leukemia. [6]
In another study Laport  et  al.  evaluated sixty-seven patients  with HLA-matched sibling
donor who received fractionated total body irradiation (FTBI) and high-dose VP16, whereas
11  patients  received  TBI/VP16/cyclophosphamide,  and  1  patient  received  TBI/VP16/
busulfan. The median age was 36 years. At the time of BMT, 62% of the patients were in
first complete remission and 38% of the patients were beyond CR1 (> CR1). The median
follow-up was 75 months The 10-year OS for the CR1 and beyond CR1 patients was 54%
and 29%, and event-free survival was 48% and 26%. The authors did not find significant
difference in relapse incidence (28% vs 41%, but non relapse mortality was significantly
higher in the beyond CR1 patients,  (31% vs 54%).  In this  study the univariate  analysis,
factors affecting event-free and overall survival were white blood cell count at diagnosis
(<  30  _  109/L vs  >  30  _  109/L)  and disease  status  (CR1 vs  >  CR1).  The median time to
relapse for CR1 and for beyond CR1 patients was 12 months and 9 months, respectively.
These  results  showed  that  FTBI/VP16  with  or  without  cyclophosphamide  confers  long-
term  survival  in  Ph+  ALL  patients  and  that  disease  status  at  the  time  of  BMT  is  an
important predictor of outcome. [7]
In these and other studies the factors that identify modifications in the transplant outcome
have been analyzed. Complications such as TRM was mainly due to infections or GVHD (graft-
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versus-host-disease), and was higher in patients with more advanced disease. Factors affecting
event-free and overall survival likewise included disease status (CR1 vs > CR1) and higher
age, with a cutoff at approximately 30 years, at the time of transplantation. [8] The intensified
preparatory regimens confer long-term survival in a subset of patients with Ph+ ALL, relapse
and TRM remain important causes of treatment failure, making success unlikely in patients
with more advanced disease. Interestingly, comparable survival data were reported for
patients with high-risk ALL with the Philadelphia chromosome and those with normal
cytogenetic; actuarial disease-free survival (DFS) at 5 years was 43% for patients in first
remission. Chronic GVHD appears to reduce the risk of relapse without increasing the risk of
TRM, whereas severe acute GVHD increases the risk of TRM without diminishing the risk of
relapse. Thus, patients who developed extensive chronic GVHD had better survivals, and
those who developed grade III-IV acute GVHD had worse survivals than did the others. [8,9]
3. Reduced-intensity conditioning allogeneic stem cell transplantation
In  order  to  decrease  the  high  TRM  associated  with  myeloablative  allogeneic  stem  cell
transplantation but still  generate a graft-versus- leukemia effect (GVLE), reduced-intensi‐
ty conditioning (RIC) regimens were developed for patients unlikely to tolerate the toxicities
of  intensive  preparative  regimens.  Overall,  several  retrospective  analyses  and  a  single
prospective study suggest that BMT with RIC is feasible in adult patients with high-risk
ALL but associated with a high probability of  treatment failure in patients transplanted
beyond CR1. [10,11,12,13] Myeloablative BMT carries considerable risk of TRM and is not
applicable to older individuals. Opinions vary on the upper age limit for the procedure; in
UKALL12/E2993, a very high TRM of nearly 40% was observed in patients older than 35
years of age receiving myeloablative BMT, resulting in a protocol limit of 40 years of age
in the current UK NCRI study, UKALL14. In some studies, patients are offered myeloabla‐
tive BMT up to the age of 55 years. [14] There are several studies that show the results of
the regimens of  reduced intensity but with different results,  selection and design which
must be interpreted with caution.
A comparative study of European Group for Blood and Marrow Transplantation (EBMT)
registry report one retrospective study where the outcome of 576 adult acute lymphoblas‐
tic leukemia patients aged > 45 years, and who received a reduced-intensity conditioning
(RIC; n=127) or myeloablative conditioning (MAC; n=449) allogeneic stem cell transplanta‐
tion  from  a  human  leukocyte  antigen-identical  sibling  while  in  complete  remission  is
assessed. With a median follow-up of 16 months, at 2 years, the cumulative incidences of
non-relapse mortality and relapse incidence were 29% (MAC) versus 21% (RIC), and 31%
(MAC) versus 47% (RIC), respectively. In a multivariate analysis, nonrelapse mortality was
decreased in RIC recipients, whereas it was associated with higher relapse rate. At 2 years,
LFS was 38% (MAC) versus 32% (RIC). In multivariate analysis, the type of conditioning
regimen (RIC vs. MAC) was not significantly associated with leukemia-free survival. For
this authors the RIC allo-SCT from a human leukocyte antigen identical donor is a potential
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therapeutic option for acute lymphoblastic leukemia patients aged > 45 years in complete
remission and not eligible for MAC allo. [15]
The RIC approaches should be vigorously pursued as part of prospective studies in order to
define their role in ALL. In Ph+ ALL in particular, inquiry into the role of TKIs after alloHSCT
is vital. The forthcoming study from the UK NCRI, UKALL14, assigned all patients with ALL
of 40 years of age or more to a nonmyeloablative approach with fludarabine, melphalan, and
alemtuzumab in an attempt to obtain good disease control with less GVHD. [14] The incidence
of TRM and disease progression in these studies was still substantial, however particularly in
patients transplanted beyond first CR. The incidence of acute (grades II-IV) and chronic GVHD
(43.2% and 65.6%, respectively) was high, but the significantly lower frequency of disease
progression in patients with cGVHD highlights the antileukemic activity of cGVHD [15]
4. Autologous stem cell transplantation
The role of autologous stem cell transplantation (ASCT) was studied most extensively in the
pre-imatinib era and has attracted little interest since then. While there are no prospective,
randomized trials comparing autologous and allogeneic SCT, treatment outcome with
conventional ASCT procedures has consistently been inferior to BMT in several retrospective
analyses due to a high relapse rate. More recently, some investigators have reevaluated the
therapeutic potential of ASCT when given in conjunction with TKI. Shin et al. describe an
approach in which Ph+ ALL patients receive imatinib as interim therapy between chemother‐
apeutic cycles and prior to autologous SCT, followed by maintenance therapy. Small patient
numbers and as yet limited duration of follow-up preclude a definite assessment of this
strategy, which can be expanded to include the more potent second-generation TKI. [15, 16]
5. Imatinib after SCT
A very important and as yet unanswered question concerns whether TKIs should be admin‐
istered after BMT and under what circumstances. The high risk of relapse in patients who are
MRD positive after SCT makes administration of an ABL-directed TKI conceptually attractive
as a measure to prevent relapse and reestablish molecular negativity. [17] Administration of
imatinib early after HCT was tested by Carpenter et al in 22 patients, 15 with Ph+ ALL and 7
with high-risk chronic myelogenous leukemia, (CML) who were enrolled in a prospective
study and given imatinib from the time of engraftment until 365 days after HCT. Before day
90, adults (n =19) tolerated a median average daily imatinib dose of 400 mg/d, and children (n
= 3) tolerated 265 mg/m2/d. The most common adverse events described by the authors were
related to imatinib administration with grade 1-3 nausea, emesis, and serum transaminase
elevations. [18]
The positive minimal residual disease (MRD) after stem cell transplantation: is associated with
a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this
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high relapse rate. This hypothesis was evaluated in another prospective study by Wassmann
and al. in 27 Ph+ALL patients that received imatinib upon detection of MRD after SCT. Bcr-
abl transcripts became undetectable in 52% of the patients, after a median of 1.5 months, (they
called earlyCRmol). All patients who achieved an earlyCRmol remained in remission for the duration
of imatinib treatment; 3 patients relapsed after imatinib was discontinued. The failure to
achieve polymerase chain reaction (PCR) negativity shortly after starting imatinib predicted
relapse which occurred in 12 of 13 patients after a median of 3 month. The DFS in early-CRmol
patients was 91% and 54% after 12 and 24 months, respectively, compared with 8% after 12
months in patients remaining MRD+. Thus in the post-transplant setting, the molecular
response to imatinib discriminates between patients with long-term DFS and patients likely
to experience relapse and who therefore should receive additional or alternative antileukemic
therapy. [19]
Burke et al between 1999 and 2006, in a single-center analysis of 32 patients with Ph+ ALL,
including pediatric patients, who underwent allo-HCT and received imatinib in either the pre-
or post-transplant period. The median age at HCT was 21.9 years, of 32 patients, 15 received
Imatinib therapy pre- or post-HCT (imatinib group) and 17 patients received either no imatinib
(n=11) or only after relapsed (n=6) (non imatinib group) There was a trend towards improved
OS, relapse-free survival and relapse at 2 years was, 61%, 67% and 13% for the imatinib group
(n = 15) as compared with the 41%, 35% and 35% for the non-imatinib group (n = 17), respec‐
tively. Cardiac toxicity and TRM at 2 years were similar between the groups. [20] Overall,
further data is needed to define the optimal use and impact of imatinib in the peri-transplant
management of patients with Ph+ ALL.
6. Monitoring of BCR-ABL in Ph+ ALL
Real-time PCR BCR-ABL quantification is often used to monitor minimal residual disease in
patients with Ph+ ALL, but optimal practice and interpretation of results is unclear. In addition,
while there is considerable standardization of methodology for p210 quantification, there is
less standardization than for p190 quantification.[17] There are conflicting reports on the
association between an initial decrease in BCR-ABL transcript level and long-term outcome.
Preudhomme C et al. In the “pre-imatinib” era, have observed a good correlation between
BCR-ABL transcript levels and the outcome which had been reported in 17 patients with Ph
+ALL. [21]
Ottmann et al. analyzed in elderly patients with de novo Ph+ALL who were randomly assigned
to induction therapy with either imatinib Ind(IM)) or multiagent, age-adapted chemotherapy
Ind(chemo). Imatinib was subsequently co-administered with consolidation chemotherapy.
The BCR-ABL transcript levels have also been correlated with response. [22] Unlike in chronic
myeloid leukemia, there is no consensus on what represents an optimal response.
Lee et al were able to demonstrate that a 3-log reduction in BCR-ABL transcripts after 1 month
of imatinib treatment strongly predicted a reduced relapse risk. The outcomes were evaluated
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for Ph+ ALL in 23 adults patients in remission treated with allogeneic bone marrow trans‐
plantation (BMT) [23]
In contrast to the data published by these authors, Yanada et al observed no association
between rapid achievement of BCR-ABL negativity and long-term outcome after an initial
imatinib/chemotherapy induction regimen in 100 patients with Ph+ ALL treated and MRD
monitoring [24]
Pfeifer et al examined the prevalence of KD mutations in newly diagnosed and Imatinib-naïve
Ph+ ALL patients and assessed their clinical relevance in the setting of uniform frontline
therapy with imatinib in combination with chemotherapy. The German Multicenter Study
Group for Adult Acute Lymphoblastic Leukemia (GMALL) trial ADE10 for newly diagnosed
elderly Ph+ ALL were retrospectively examined for the presence of BCR/ABL KD mutation by
denaturing high-performance liquid chromatography (DHPLC),cDNA sequencing and allele-
specific polymerase chain reaction (PCR). A KD mutation was detected in a minor subpopu‐
lation of leukemic cells in 40% of newly diagnosed and imatinib naïve patients. At relapse the
domin cell clone harbored an identical mutation in 90% of the cases, the overall prevalence of
mutations at relapse was 80 %. P loop mutations predominated and were not associated with
an inferior hematologic or molecular remission rate or shorter rmission duration compared
with unmutated BCR/ABL. BCR/ABL mutations conferring high level imatinib resistance are
present in a substantial proportion of patients with de novo Ph+ ALL and eventually give rise
to relapse.[25]
Soverini et al. analyzed samples collected at diagnosis from 15 patients with Philadelphia-
positive acute lymphoblastic leukemia who subsequently received tyrosine kinase inhibitor
therapy (dasatinib) by cloning the BCR-ABL kinase domain in a bacterial vector and sequenc‐
ing 200 independent clones per sample. Mutations at relatively low levels (2-4 clones out of
200) could be detected in all patients--eight who relapsed and seven who achieved persistent
remission. Each patient had evidence of two to eight different mutations, the majority of which
have never been reported in association with resistance to tyrosine kinase inhibitors. They
suggest that the BCR-ABL kinase domain is prone to randomly accumulate point mutations,
although the presence of these mutations in a relatively small leukemic subclone does not
always preclude a primary response to tyrosine Kinase inhibitor. [26]
So much imatinib or dasatinib regimens can be achieving complete clinical response in 95
-100% of patients.
Eligible patients will be treated with alloHSCT wherever possible, and for these patients, BCR-
ABL monitoring early in the course of the disease is unlikely to change practice at present. For
patients not receiving alloHSCT, serial monitoring during initial therapy is of more relevance
because it might prompt a switch of therapy before hematological relapse. [17]
At present, the evidence suggests that BCR-ABL by RTQ-PCR should be monitored and must
be combined with screening for BCR/ABL domain mutations (in case of suspected resistance)
after alloHSCT and that reemergence of BCR-ABL is a rational basis for intervention. [27]
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7. Resistence
Approximately 80 %to 90% of patients with Ph+ ALL who relapse while on imatinib are found
to have BCR/ABL mutation with predominance of P-loop and T315I mutations. With dasatinib
relapse is most frequently associated with T315I mutation, whereas P-loop mutations are less
common. [28] With variable frequency, the mutations can be present at the time of diagnose.
Pfeifer et al detected low levels of mutations in pretreated patients with imatinib with Ph+ ALL
who, at the time of relapse, presented the same mutated dominant clone in most of the cases.
Soverini et al also reported a high frequency of BCR/ABL mutations which were lately found
at the time of relapse. [25,26] Mutations can also be acquired or emerge under the selection
pressure of TKI treatment.
Other additional mechanisms of resistance to therapy with TKI have also been suggested, such
as cytogenetic abnormalities in addition to Ph chromosome which are present in approxi‐
mately one third of cases of adult leukemia and have been associated with inferior outcome.
Members of the SRC family of kinase have been implicated in leukemogenesis and in the
development of imatinib resistance in BCR/ABL positive ALL, suggesting that simultaneous
inhibition of Src and Bcr/Abl kinases may benefit individuals with Ph+ acute leukemia. [29, 30]
8. Relapses in Ph+ acute lymphoblastic leukemia
Relapsed ALL is a clinical problem, and outcomes are extremely poor. Fielding et al in the
UKALL12/ECOG study, examined 609 adults with recurring ALL, where the OS of newly
diagnosed patients was 38% at 5 years, OS at 5 years after relapse was 7%. [31] The CR2 is
possible in only ∼ 50% of chemotherapy-treated patients. Many young patients with Ph+ ALL
will have already received alloHSCT, making salvage harder and with more toxicity, partic‐
ularly if chemotherapy reinduction is under consideration. Nevertheless a phase 2 study of
dasatinib 140 mg/d in patients who relapsed after imatinib-containing regimens demonstrated
that approximately half of the patients could achieve a CR2 with modest toxicity. However,
median remission duration was only 3.3 months. Under these circumstances, a second allo-
HSCT might be considered.[32] Ishida et published case report which shows a positive
outcome for a patient who received dasatinib followed by a RIC alloHSCT after imatinib and
myeloablative allo-HSCT which failed to control the disease. All reports of allo-HSCT show
less than an ideal outcome in patients beyond CR1. However, many of these were reported
before the advent of TKIs, which might, in selected circumstances, allow for second definitive
transplantation procedures [33] Among the strategies to treat Ph + ALL relapse after Allo-SCT
we will mention donor lymphocyte infusion. This treatment seems to be effective in CML, but
it is less useful in ALL maybe due to the immune escape mechanisms of the blastic cells.
Likewise, the addition of chemotherapy to ILD is not associated with a better prognosis.
Immunotherapy with donor lymphocyte infusion (DLI) and imatinib appears to be well
tolerated but it is rarely and in general only transiently effective. A rationale for the combined
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use of DLI and second-generation TKIs such as nilotinib is suggested by case reports, but
prospectively collected data are as yet not available. [34]
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